As the results of the studies in a murine tumor model strongly suggest that the activity of agents targeting PD-L1 relies on their binding to activating FcγR resulting in the altering myeloid subsets within the tumor microenvironment [277]. The gene discussed is FCGR2A; the disease is neoplasm.